Insight Pharma Reports
Insight Pharma Reports is the premier life science information provider. They cover key issues in drug discovery and development. Their reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. Written by experts in consulting and industry and supported by hundreds of hours of primary and secondary research.
Title ![]() | Date ![]() | Price ![]() |
|---|---|---|
| Approaches to Reducing Phase II Attrition | May 2009 | £2,255 |
| Medicinal Chemistry for Drug Discovery Significance of Recent Trends | Mar 2009 | £2,255 |
| Direct-To-Consumer Genetic Testing Business Prospects in the United States | Mar 2009 | £2,255 |
| Protease Inhibitors Innovation Drives Drug Pipeline | Feb 2009 | £2,255 |
| Molecular Diagnostics A Dynamic and Rapidly Broadening Market Overview | Jan 2009 | £2,255 |
| Biomedical Imaging From Drug Target Discovery to Medical Diagnostics | Dec 2008 | £2,255 |
| Conducting Clinical Trials in Europe An Insider's Analysis | Dec 2008 | £2,255 |
| Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders | Dec 2008 | £2,255 |
| Stem Cells Come of Age | Nov 2008 | £2,255 |
| GPCRs: Dawn of a New Era? | Oct 2008 | £2,255 |
| Immunotherapies and Vaccines for Cancer and Infectious Diseases | Oct 2008 | £2,255 |
| Strategic Management of Resources and Portfolios Structuring Risk to Maximize Opportunity in Pharmaceutical R&D | Aug 2008 | £2,255 |
| Antibiotic R&D Resolving the Paradox between Unmet Medical Need and Commercial Incentive | Jul 2008 | £2,255 |
| Cancer Biomarkers Adoption Is Driving Growth | Jul 2008 | £2,255 |
| Cardiotoxicity: Issues, Technologies, and Solutions for the Future | May 2008 | £2,255 |
| Blood-Brain Barrier Bridging Options for Drug Discovery and Development | May 2008 | £675 |
| Systems Biology A Disruptive Technology | May 2008 | £675 |
| Inflammatory Directions Strategies for Six Diseases with Unmet Needs | Apr 2008 | £675 |
| MicroRNAs Commercial Products on the Horizon | Mar 2008 | £675 |
| Epigenetics Technologies, Applications, and the Commercial Landscape | Feb 2008 | £675 |
call +44 (0) 20 7060 7474
or email us


previous













